Navigation Links
Labtec’s Next Generation Pain Patch Successful in Clinical,Studies

LANGENFELD, Germany, April 25, 2007-Labtec GmbH (Langenfeld, Germany), a specialty pharmaceutics company announces positive results from a multiple dose clinical study for their proprietary Sufentanil transdermal patch.

“Today, we are pleased to announce the successful completion of the second clinical trial for our Sufentanil TDS®. Our goal for this program was to complete this study in the first half of 2007,” says Dr. Armin Breitenbach, Labtec's Director of Pharmaceutical Development. “Based on the positive results of the first Phase I trial for our Sufentanil patch that showed good safety, tolerability and extended drug release, we initiated this trial end of last year. The objectives to demonstrate effective plasma levels and safety of repetitive applications of our Sufentanil patch were fully met. We believe that this product, once approved, will provide a significant improvement over currently available pain management therapies on the market today.”

Labtec's transdermal Sufentanil product is intended to provide extended chronic pain relief for several days. The patch is not only very small but at the same time has an unusually low drug content. The proprietary formulation releases the drug with an unparalleled efficiency. Additional patient comfort is achieved by the use of a special non-woven backing. Unlike most backing films used in transdermal systems, this material is non-occlusive, allows the skin to breathe and maintains its integrity throughout the application period.

“After the huge success story of our Fentanyl patch, which is marketed by our licensee ratiopharm and several other leading generic companies in Europe, we are looking forward to see our Sufentanil TDS® move forward. In our opinion this transdermal patch is the logical next generation product for severe chronic pain. Sufentanil is one of the most potent drugs in its class,
'"/>




Page: 1 2

Related medicine technology :

1. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
2. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
3. Medtronic Announces Positive Nine-Month Results for Endeavor Resolute Next Generation Drug-Eluting Stent at EuroPCR
4. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
5. CeNeRx BioPharma Announces Positive Phase I Results in First Human Trial of Third Generation RIMA Antidepressant
6. Iomai Dose-Ranging Trial Demonstrates Needle-Free Patch Vaccine for Travelers Diarrhea Stimulates Immune Response Even at Low Doses
7. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
10. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
11. Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Labtec Next Generation Pain Patch Successful Clinical Studies
(Date:5/17/2013)... , May 17, 2013  Orexigen® Therapeutics, Inc. (Nasdaq: ... a company overview at the UBS Global Healthcare Conference in ... for Wednesday, May 22 nd at 11 a.m. Eastern ... of the presentation, please visit the Investor Relations section of ... will be available for 14 days after the event. ...
(Date:5/17/2013)... 17, 2013  Sony Biotechnology Inc. ("Sony") today announced the ... and 130um sorting chip.  Sony will also be exhibiting its ... SH800 Cell Sorter, the EC800 flow cytometer, and new SP6800 ... 2013, which will be held at the San ... California , from May 20 - 22.  ...
(Date:5/17/2013)... -- Research explores data on treatments ...   to   be presented Shire ... global specialty biopharmaceutical company, announces that it will present ... Psychiatric Association (APA) 166th Annual Meeting in ... presented represent Shire,s ongoing commitment to the clinical research ...
Breaking Medicine Technology:Sony Delivers New Technology for Science to CYTO 2013 2Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 2Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 3Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 4Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 5Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 6Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 7Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 8Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 9Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 10
... Ontario, Sept. 2, 2011 Valeant Pharmaceuticals International, Inc. (NYSE: ... members of its senior management team will be participating at ... and Chief Executive Officer will make a presentation at the ... London on Thursday, September 15, 2011 at 10:35 a.m. BT ...
... Lifetime Products, Inc. -- a worldwide Utah-based manufacturer ... storage sheds, and lawn and garden products -- announced ... adding a new Health and Wellness product category. ... will feature products like the award-winning Lifetime Tru-Motion™ ...
Cached Medicine Technology:Lifetime Products Enters New Product Category: Health and Wellness 2
(Date:5/20/2013)... ESMO 32nd ESTRO European Cancer Congress will take ... ), from Friday 17 September to Tuesday 1 October ... The congress will build on the success of the ... Medical Oncology) and ESTRO (European Society for Therapeutic Radiology ... in Europe to offer presentations of cutting-edge research across ...
(Date:5/20/2013)... 2013 Ariosa Diagnostics, maker of the ... syndrome and other chromosome conditions, has announced today the ... conceived or conceived using the patient’s own egg. ... analysis as an option to those women electing to ... the evaluation of fetal sex and sex chromosome genetic ...
(Date:5/20/2013)... Soliant Health, a leading specialty healthcare staffing provider ... its fifth annual Most Beautiful Hospitals in the U.S. contest. ... decided to bypass its routine selection process and include not ... be in the running for the 2013 Most Beautiful Hospitals ... and runs through June 23. Winners will be revealed on ...
(Date:5/20/2013)... Cayman, Cayman Islands (PRWEB) May 20, 2013 ... knowledge-based, high tech Special Economic Zone in the ... Referral Network, an initiative to grow the zone’s ... with Cayman’s business-friendly environment and tax benefits are ... many of them referrals from zone channel partners. ...
(Date:5/20/2013)... Jointly established by The Hong ... (Sichuan U), China's first Institute for Disaster ... officially opened. Both institutions also held the ... Reduction" to conclude lessons learnt from Wenchuan ... Margareta Wahlström, Special Representative of the Secretary-General ...
Breaking Medicine News(10 mins):Health News:Media registration for the European Cancer Congress 2Health News:Ariosa Diagnostics Expands Harmony Prenatal Test to Twin Pregnancies and Launches New X,Y Analysis Test 2Health News:Vote for Soliant Health's 2013 Most Beautiful Hospitals in the U.S. 2Health News:Vote for Soliant Health's 2013 Most Beautiful Hospitals in the U.S. 3Health News:Vote for Soliant Health's 2013 Most Beautiful Hospitals in the U.S. 4Health News:Vote for Soliant Health's 2013 Most Beautiful Hospitals in the U.S. 5Health News:Vote for Soliant Health's 2013 Most Beautiful Hospitals in the U.S. 6Health News:Vote for Soliant Health's 2013 Most Beautiful Hospitals in the U.S. 7Health News:Vote for Soliant Health's 2013 Most Beautiful Hospitals in the U.S. 8Health News:Vote for Soliant Health's 2013 Most Beautiful Hospitals in the U.S. 9Health News:Cayman Enterprise City Introduces Referral Network 2Health News:Cayman Enterprise City Introduces Referral Network 3Health News:PolyU and Sichuan U Jointly Set Up China's First Institute for Disaster Management and Reconstruction 2Health News:PolyU and Sichuan U Jointly Set Up China's First Institute for Disaster Management and Reconstruction 3
... identified a possible cause for the loss of a tumour ... development of more aggressive forms of prostate cancer. , ... prostate cancer develops because we now have some insight into ... Jeremy Squire, a professor in the Department of Pathology and ...
... HPV infection is more common among men than women, explaining ... HPV related head and neck cancer, according to a study ... by AHNS, ASCO, ASTRO and SNM., Human papillomavirus, or HPV, ... neck cancer that are becoming more prominent in the United ...
... or without chemotherapy is less effective for patients with HIV ... patients who do not have HIV, according to a study ... by AHNS, ASCO, ASTRO and SNM. , Treating head and ... Because of the advancements in treating HIV, these patients are ...
... of positron emission tomography/computed tomography (PET/CT) scans in head ... before they become clinically apparent and may improve the ... presented at the Multidisciplinary Head and Neck Cancer Symposium, ... is a relatively new test and its use as ...
... HOUSTON Scientists have connected two signature characteristics of pancreatic ... a new potential target for drugs to treat one of ... in the journal Cancer Cell and led by ... connected the molecular dots between: Mutated versions ...
... By Steven Reinberg HealthDay Reporter , WEDNESDAY, ... developing high blood pressure, diabetes or other risk factors for ... attack or stroke by age 80 than their less healthy ... to middle age with an optimal profile, it,s really like ...
Cached Medicine News:Health News:Oral HPV infection, HPV-related cancers more common in men 2Health News:Standard treatments for head and neck cancer less effective in HIV-positive patients 2Health News:Mutated Kras spins a molecular loop that launches pancreatic cancer 2Health News:Mutated Kras spins a molecular loop that launches pancreatic cancer 3Health News:Optimal Heart Health Starts Early: Study 2Health News:Optimal Heart Health Starts Early: Study 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: